ReWalk Robotics Ltd. (NASDAQ:LFWD – Get Free Report) Director Michael Swinford acquired 21,622 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was bought at an average cost of $2.03 per share, for a total transaction of $43,892.66. Following the completion of the purchase, the director now owns 65,040 shares of the company’s stock, valued at $132,031.20. This trade represents a 49.80 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Michael Swinford also recently made the following trade(s):
- On Friday, November 22nd, Michael Swinford acquired 16,907 shares of ReWalk Robotics stock. The stock was acquired at an average price of $1.83 per share, with a total value of $30,939.81.
- On Wednesday, November 20th, Michael Swinford purchased 16,471 shares of ReWalk Robotics stock. The shares were purchased at an average cost of $1.84 per share, for a total transaction of $30,306.64.
ReWalk Robotics Stock Performance
LFWD opened at $2.10 on Friday. The stock’s 50 day simple moving average is $2.52 and its 200 day simple moving average is $3.48. ReWalk Robotics Ltd. has a 1 year low of $1.70 and a 1 year high of $9.10.
Institutional Trading of ReWalk Robotics
A hedge fund recently bought a new stake in ReWalk Robotics stock. Dimensional Fund Advisors LP purchased a new stake in shares of ReWalk Robotics Ltd. (NASDAQ:LFWD – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 13,548 shares of the company’s stock, valued at approximately $54,000. Dimensional Fund Advisors LP owned 0.16% of ReWalk Robotics as of its most recent filing with the Securities & Exchange Commission. 26.76% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of ReWalk Robotics in a report on Wednesday, November 13th.
Check Out Our Latest Report on ReWalk Robotics
ReWalk Robotics Company Profile
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.
Featured Articles
- Five stocks we like better than ReWalk Robotics
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- Quiet Period Expirations Explained
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- How to Read Stock Charts for Beginners
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for ReWalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.